Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock - Dyne Therapeutics (NASDAQ:DYN)

Core Viewpoint - Dyne Therapeutics, Inc. has announced an upsized public offering of 18,980,478 shares at a price of $18.44 per share, aiming to raise approximately $350 million in gross proceeds before expenses [1]. Group 1: Offering Details - The public offering is expected to close around December 11, 2025, subject to customary closing conditions [1]. - Dyne has granted underwriters a 30-day option to purchase an additional 2,847,071 shares at the public offering price [1]. - Morgan Stanley, Jefferies, Stifel, and Guggenheim Securities are acting as joint book-running managers for the offering [2]. Group 2: Regulatory Information - The offering is made under a shelf registration statement on Form S-3 filed with the SEC on March 5, 2024, which became effective upon filing [3]. - A preliminary prospectus supplement has been filed with the SEC, and a final prospectus will also be filed [3]. Group 3: Company Overview - Dyne Therapeutics focuses on delivering functional improvement for individuals with genetically driven neuromuscular diseases [5]. - The company is developing therapeutics targeting muscle and the central nervous system, with clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), as well as preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease [5].